Ketoconazole HRA is indicated for the treatment of endogenous Cushing's syndrome in adults and adolescents above the age of 12 years.
A diagnostic aid in the differential diagnosis of ACTH-dependent Cushing's syndrome. The management of patients with Cushing's syndrome. In conjunction with glucocorticosteroids in the treatment of resistant oedema due to increased aldosterone secretion in patients suffering from cirrhosis, nephrosis and congestive heart failure.
Merck KGaA announced the Multiple Sclerosis Journal publication of data outlining the effects of Mavenclad (cladribine tablets) treatment on two...
Strongbridge Biopharma announced the top-line findings from the extended evaluation phase of the pivotal Phase III SONICS study of Recorlev...
Strongbridge Biopharma plc, announced top-line results from the multinational, pivotal Phase III SONICS study evaluating Recorlev (levoketoconazole) for the treatment...